The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis

BACKGROUND: A combination of temozolomide (TMZ) and radiotherapy and subsequent adjuvant chemotherapy is the gold standard of treatment for glioblastoma (GB). Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Ke-Li, Huang, Song, Wu, Yu-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016281/
https://www.ncbi.nlm.nih.gov/pubmed/29950856
http://dx.doi.org/10.2147/OTT.S156723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016281/
https://www.ncbi.nlm.nih.gov/pubmed/29950856
http://dx.doi.org/10.2147/OTT.S156723

Ejemplares similares